Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vildagliptin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 17/20 | 1.00 |
| ▸ | FAP | Q12884 | 1/20 | 1.00 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 1.00 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 1.00 |
| ▸ | PREP | P48147 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vildagliptin SCHEMBL27193113 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL665401 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL29369942 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL671629 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL665400 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL16823370 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL16153676 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL16155482 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL16579 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP | |
| Vildagliptin SCHEMBL354910 | 1.00 | DPP4 (1.00) | DPP4FAPDPP8DPP9PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120029032-A1 | MATRIX-TYPE SUSTAINED RELEASE PREPARATION CONTAINING BASIC ADDITIVE | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2012-02-02 | — | — | US | disclosed |
| US-20120029032-A1 | MATRIX-TYPE SUSTAINED RELEASE PREPARATION CONTAINING BASIC ADDITIVE | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029032-A1 | MATRIX-TYPE SUSTAINED RELEASE PREPARATION CONTAINING BASIC ADDITIVE | MMP7, COL2A1, MMP17 | DPP4 1829/4885FAP 1397/4885DPP8 2031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.